top of page


Our Management

Get to know the leaders of Solaris Pharma Corporation

Satish Pejaver, PhD


Satish Pejaver, PhD, currently serves on the board of Solaris Pharma and is responsible for overall management of the company. He was instrumental in bringing in the initial investment to form the company and is one of its founding members.  He also facilitated the additional investment required for developing its deep product pipeline. Dr. Pejaver brings in a wealth of leadership and management skills and more than 25 years of experience in the pharmaceutical industry.  He managed multiple groups at Baxter Anesthesia and Critical Care and was part of the management team that built a very successful generic program (revenues 1B in 4+ years).  More recently he was part of the management of a start-up company, InnoPharma, where he built and managed a highly productive R&D, Regulatory and Clinical team resulting in 30+ complex and specialty product regulatory filings resulting in multiple approvals in a 4 year time span. He was also part of the management team that was responsible for guiding the sale of InnoPharma to Pfizer which successfully closed in September 2014. Prior to joining Solaris, Dr. Pejaver was Vice President and Operational Site Head of the InnoPharma division within Pfizer.  He was responsible for product development, approval and commercialization of products from this site.  He was also responsible for managing P&L of the business unit.
Dr. Pejaver has 24 issued/filed US patents and 23 issued/filed WO patents

Pejaver, Satish_2x2.jpg

Shalin Jani, MS

COO (EVP) and Head of Regulatory Affairs

Shalin Jani, M.S. brings in more than 18 years of experience in the pharmaceutical industry.  At Solaris Pharma he is responsible for Portfolio, Business Development & Licensing, Sales and Marketing, Procurement, CMO Selection/Alliance Management, Budgeting and Forecasting, Commercialization (scale-up through launch), and Regulatory Affairs.
Shalin is an experienced Operations, R&D, Clinical, and Regulatory professional focused in generic, 505b1, and 505b2 space with tenures at leading companies such as Teva, Sandoz, Actavis, and Pfizer. 
Shalin has a Masters in Cell and Developmental Biology from UMDNJ/Rutgers University and B.S. in Molecular Biology and Biochemistry from Rutgers University.

bottom of page